Targets › GRIN2
1 program from 1 company in 1 trial: 1 Phase 2; Psychiatry; next expected readout Jul 2027.
Open in Phaseline: the race on GRIN2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Institute of Mental Health (NIMH) | (2R,6R)-hydroxynorketamine Enhancer of synaptic glutamate release | GRIN1, GRIN2 | Phase 2 | Suicide | Jul 2027 |
Suicide (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.